Tags

Type your tag names separated by a space and hit enter

Is pleomorphic lobular carcinoma really a distinct clinical entity?
J Surg Oncol. 2008 Oct 01; 98(5):314-7.JS

Abstract

BACKGROUND

Attempts to define the clinical behavior of pleomorphic lobular carcinoma (PLC) have been limited to small series, and clinical management strategies have yet to be established. We describe our experience with PLC as compared to classic ILC and invasive ductal carcinoma (IDC).

METHODS

From 9/1996 to 5/2003, clinical and histopathologic data for 5,635 patients undergoing primary surgical treatment and sentinel lymph node biopsy for breast cancer were collected. Four hundred eighty one (8.5%) patients were diagnosed with ILC; 3,978 (70.6%) with IDC. Of those with ILC, 356 (74%) patients had material available for pathologic re-review and comprise our study population: 52 were classified as PLC; 298 were classified as classic ILC; and 6 cases were reclassified as IDC. We compared clinical, pathologic, and treatment factors for patients with PLC, ILC, and IDC using the Wilcoxon rank sum and Fisher's exact tests.

RESULTS

PLC were larger than ILC and IDC (20 vs. 15 vs. 13, P < 0.001), had more positive nodes (median 1 vs. 0 vs. 0, P < 0.05) and more frequently required mastectomy (63.5% vs. 38.7% vs. 28.8%, P < 0.001). In addition, more patients with PLC had developed metastatic disease compared to patients with ILC (11.5% vs. 3.7%, P < 0.05).

CONCLUSIONS

These findings suggest that PLC is a distinct clinical entity that presents at a more advanced stage and may require more aggressive surgical and adjuvant treatment.

Authors+Show Affiliations

Department of Surgery, Swedish Cancer Institute, Seattle, Washington, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18668643

Citation

Buchanan, Claire L., et al. "Is Pleomorphic Lobular Carcinoma Really a Distinct Clinical Entity?" Journal of Surgical Oncology, vol. 98, no. 5, 2008, pp. 314-7.
Buchanan CL, Flynn LW, Murray MP, et al. Is pleomorphic lobular carcinoma really a distinct clinical entity? J Surg Oncol. 2008;98(5):314-7.
Buchanan, C. L., Flynn, L. W., Murray, M. P., Darvishian, F., Cranor, M. L., Fey, J. V., King, T. A., Tan, L. K., & Sclafani, L. M. (2008). Is pleomorphic lobular carcinoma really a distinct clinical entity? Journal of Surgical Oncology, 98(5), 314-7. https://doi.org/10.1002/jso.21121
Buchanan CL, et al. Is Pleomorphic Lobular Carcinoma Really a Distinct Clinical Entity. J Surg Oncol. 2008 Oct 1;98(5):314-7. PubMed PMID: 18668643.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is pleomorphic lobular carcinoma really a distinct clinical entity? AU - Buchanan,Claire L, AU - Flynn,Laurie W, AU - Murray,Melissa P, AU - Darvishian,Farbod, AU - Cranor,Milicent L, AU - Fey,Jane V, AU - King,Tari A, AU - Tan,Lee K, AU - Sclafani,Lisa M, PY - 2008/8/1/pubmed PY - 2008/11/7/medline PY - 2008/8/1/entrez SP - 314 EP - 7 JF - Journal of surgical oncology JO - J Surg Oncol VL - 98 IS - 5 N2 - BACKGROUND: Attempts to define the clinical behavior of pleomorphic lobular carcinoma (PLC) have been limited to small series, and clinical management strategies have yet to be established. We describe our experience with PLC as compared to classic ILC and invasive ductal carcinoma (IDC). METHODS: From 9/1996 to 5/2003, clinical and histopathologic data for 5,635 patients undergoing primary surgical treatment and sentinel lymph node biopsy for breast cancer were collected. Four hundred eighty one (8.5%) patients were diagnosed with ILC; 3,978 (70.6%) with IDC. Of those with ILC, 356 (74%) patients had material available for pathologic re-review and comprise our study population: 52 were classified as PLC; 298 were classified as classic ILC; and 6 cases were reclassified as IDC. We compared clinical, pathologic, and treatment factors for patients with PLC, ILC, and IDC using the Wilcoxon rank sum and Fisher's exact tests. RESULTS: PLC were larger than ILC and IDC (20 vs. 15 vs. 13, P < 0.001), had more positive nodes (median 1 vs. 0 vs. 0, P < 0.05) and more frequently required mastectomy (63.5% vs. 38.7% vs. 28.8%, P < 0.001). In addition, more patients with PLC had developed metastatic disease compared to patients with ILC (11.5% vs. 3.7%, P < 0.05). CONCLUSIONS: These findings suggest that PLC is a distinct clinical entity that presents at a more advanced stage and may require more aggressive surgical and adjuvant treatment. SN - 1096-9098 UR - https://www.unboundmedicine.com/medline/citation/18668643/Is_pleomorphic_lobular_carcinoma_really_a_distinct_clinical_entity L2 - https://doi.org/10.1002/jso.21121 DB - PRIME DP - Unbound Medicine ER -